KCM
ENTA icon

Kingdon Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Kingdon Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-75,000
Closed -$1.71M – 192
2013
Q3 		$1.71M Hold
75,000
– – 0.08% 167
2013
Q2 		$1.33M Buy
+75,000
New +$1.46M 0.08% 178

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kingdon Capital Management's ENTA Position: Q4 2013 in Review

Kingdon Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2013, closing a stake of 75,000 shares — an estimated $1.71M sold.

Kingdon Capital Management first reported a position in ENTA in Q2 2013 and held it in 2 quarters. The position peaked at $1.71M in Q3 2013. 66 funds tracked by Wall St. Rank hold ENTA as of Q4 2013.

  • Kingdon Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Kingdon Capital Management sold 75,000 Enanta Pharmaceuticals shares in Q4 2013, an estimated $1.71M.
  • Kingdon Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Kingdon Capital Management's Enanta Pharmaceuticals position peaked at $1.71M in Q3 2013.
  • 66 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2013.

Based on Kingdon Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.